Ulrich Fischer-Rasokat

Dr. Ulrich Fischer-Rasokat


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
UFUlrich Fischer-Rasokat
Ulrich Fischer-Rasokat
MRMatthias Renker
Matthias Renker
CLChristoph Liebetrau
Christoph Liebetrau
ALArnaud van Linden
Arnaud van Linden
MAMani Arsalan
Mani Arsalan
WKWon-Keun Kim
Won-Keun Kim

5 October 2019 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
WKWon-Keun Kim
Won-Keun Kim
CLChristoph Liebetrau
Christoph Liebetrau
UFUlrich Fischer-Rasokat
Ulrich Fischer-Rasokat
MRMatthias Renker
Matthias Renker
ARAndreas Rolf
Andreas Rolf
CHChristian W. Hamm
Christian W. Hamm

11 February 2025 in Circulation
Verified
Journal Article
Closed access
FRFelix Rudolph
Felix Rudolph
MGMartin Geyer
Martin Geyer
SBStephan Baldus
Stephan Baldus
VLValeria Maria De Luca
Valeria Maria De Luca
TDTorsten Doenst
Torsten Doenst
CIChristos Iliadis
Christos Iliadis

26 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
UFUlrich Fischer-Rasokat
Ulrich Fischer-Rasokat
MRMatthias Renker
Matthias Renker
CLChristoph Liebetrau
Christoph Liebetrau
MWMaren Weferling
Maren Weferling
ARAndreas Rolf
Andreas Rolf
WKWon-Keun Kim
Won-Keun Kim
Patients with aortic stenosis (AS) may have concomitant heart failure (HF) that determines prognosis despite successful transcatheter aortic valve implantation (TAVI). We compared outcomes of TAVI patients with low stroke volume index (SVI) ≤35 ml/m2 body surface area in different HF classes. Patients treated by transfemoral TAVI at our center (n = 1822) were classified as 1) ‘HF with preserved ejection fraction (EF)’ (HFpEF, EF ≥50%), 2) ‘HF with mid-range EF’ (HFmrEF, EF 40–49%), or 3) ‘HF with reduced EF’ (HFrEF, EF 35 ml/m2 served as controls. The prevalence of cardiovascular disease and symptoms increased stepwise from controls (n = 968) to patients with HFpEF (n = 591), HFmrEF (n = 97), and HFrEF (n = 166). Mortality tended to be highest in HFrEF patients 30 days post-procedure, and it became significant after one year: 10.2% (controls), 13.5% (HFpEF), 13.4% (HFmrEF), and 23.5% (HFrEF). However, symptomatic improvement in survivors of all groups was achieved in the majority of patients without differences among groups. Patients with AS and HF benefit from TAVI with respect to symptom alleviation. TAVI in patients with HFpEF and HFmrEF led to an identical, favorable post-procedural prognosis that was significantly better than that of patients with HFrEF, which remains a high-risk population.

20 April 2022 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
UFUlrich Fischer-Rasokat
Ulrich Fischer-Rasokat
CBCeline Bänsch
Celine Bänsch
MRMatthias Renker
Matthias Renker
ARAndreas Rolf
Andreas Rolf
ECEfstratios I Charitos
Efstratios I Charitos
WKWon-Keun Kim
Won-Keun Kim
Aims: The objective of the study was to determine the effect of renin–angiotensin system inhibitors (RASI) on the survival of subgroups of patients with aortic stenosis after transcatheter aortic valve implantation (TAVI) and to assess the impact of types and dosages of RASI on outcomes. Methods and results: This single-centre, retrospective analysis included 2862 patients (n = 2227 with RASI and n = 635 without RASI) after successful TAVI. Propensity score matching established comparable patient populations (n = 625 per group). Survival was analysed by Kaplan–Meier curves and Cox regression and was corrected for baseline, procedural, and medical parameters. Self-reported adherence to RASI therapy 3 months after hospital discharge was 94%. Three-year all-cause mortality rates were 12.3% and 20.2% for patients with or without RASI, respectively (log-rank <0.001). In the matched study populations, mortality rates were 14.2% vs. 20.0% (log-rank <0.03). RASI was particularly beneficial in patients with ejection fraction <40% [adjusted hazard ratio (HR) and 95% confidence interval 0.50 (0.29–0.87)], EuroScore II ≥4% [HR 0.47 (0.35–0.65)], or low-flow, low-gradient aortic stenosis [HR 0.53 (0.31–0.93)] who were also on beta-blockers and statins. An association between discharge dosage and survival was observed, with HR 0.75 (0.58–0.96) and 0.57 (0.44–0.72) for patients on <50% and ≥50% target dose, respectively. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) reduced mortality rates similarly (13.9% vs. 9.8%, log-rank 0.103). Conclusions: The beneficial association between RASI after TAVI and improved survival during follow-up is particularly evident in high-risk patients and may be dose dependent. No superiority was noted in the effectiveness of ACEI or ARB.

16 December 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
ARAndreas Rolf
Andreas Rolf
TKTill Keller
Till Keller
JWJan Sebastian Wolter
Jan Sebastian Wolter
SKSteffen Daniel Kriechbaum
Steffen Daniel Kriechbaum
MWMaren Weferling
Maren Weferling
JTJulia Treiber
Julia Treiber
Cardiac magnetic resonance (CMR) is currently the gold standard for evaluating right ventricular (RV) function, which is critical in patients with pulmonary hypertension. CMR feature-tracking (FT) strain analysis has emerged as a technique to detect subtle changes. However, the dependence of RV strain on load is still a matter of debate. The aim of this study was to measure the afterload dependence of RV strain and to correlate it with surrogate markers of contractility in a cohort of patients with chronic thromboembolic pulmonary hypertension (CTEPH) under two different loading conditions before and after pulmonary endarterectomy (PEA). Between 2009 and 2022, 496 patients with 601 CMR examinations were retrospectively identified from our CTEPH cohort, and the results of 194 examinations with right heart catheterization within 24 h were available. The CMR FT strain (longitudinal (GLS) and circumferential (GCS)) was computed on steady-state free precession (SSFP) cine CMR sequences. The effective pulmonary arterial elastance (Ea) and RV chamber elastance (Ees) were approximated by dividing mean pulmonary arterial pressure by the indexed stroke volume or end-systolic volume, respectively. GLS and GCS correlated significantly with Ea and Ees/Ea in the overall cohort and individually before and after PEA. There was no general correlation with Ees; however, under high afterload, before PEA, Ees correlated significantly. The results show that RV GLS and GCS are highly afterload-dependent and reflect ventriculoarterial coupling. Ees was significantly correlated with strain only under high loading conditions, which probably reflects contractile adaptation to pulsatile load rather than contractility in general.